Yoshihiko Hirao


Ontology type: schema:Person     


Person Info

NAME

Yoshihiko

SURNAME

Hirao

Publications in SciGraph latest 50 shown

  • 2015-10-09 Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan in BMC CANCER
  • 2015-05-20 Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy in BMC CANCER
  • 2015-01-03 Estimated functional renal parenchymal volume predicts the split renal function following renal surgery in WORLD JOURNAL OF UROLOGY
  • 2014-08-03 Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid in BMC UROLOGY
  • 2014-04-29 Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer in BMC UROLOGY
  • 2014-03-28 Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2014-03-19 Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume in WORLD JOURNAL OF SURGICAL ONCOLOGY
  • 2013-06-04 Diagnostic markers of urothelial cancer based on DNA methylation analysis in BMC CANCER
  • 2013-02-09 Erratum to: Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2013-01-05 Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model in BMC UROLOGY
  • 2012-11-16 Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection in WORLD JOURNAL OF SURGICAL ONCOLOGY
  • 2012-09-14 Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer in BMC UROLOGY
  • 2011-09-20 Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2011-04-27 The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration in BMC UROLOGY
  • 2011-03-25 Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2011-02-18 Evaluation of metastatic potential of prostate cancer in ONCOLOGY REVIEWS
  • 2009-07-14 Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2008-05-20 Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2008-04 5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2008-01-31 Polypoid endometriosis of the ureter mimicking fibroepithelial polyps in JAPANESE JOURNAL OF RADIOLOGY
  • 2008-01-08 Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2007-03-06 Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2006-06-13 Quality of care associated with number of cases seen and self-reports of clinical competence for Japanese physicians-in-training in internal medicine in BMC MEDICAL EDUCATION
  • 2005-07-19 Erratum: Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene in LABORATORY INVESTIGATION
  • 2005-05-09 Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene in LABORATORY INVESTIGATION
  • 2005-04 The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2004-08-19 A 4-year-old girl with autosomal dominant polycystic kidney disease complicated by a ruptured intracranial aneurysm in EUROPEAN JOURNAL OF PEDIATRICS
  • 2004-06 Metal stent placement for two patients with post-transplantation renal artery stenosis, using intravascular ultrasound imaging in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 2004-03 Association between pentosidine and arteriosclerosis in patients receiving hemodialysis in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 2003 Clinical Practice Guideline for Benign Prostate Hyperplasia in Japan in CLINICAL GUIDELINES IN UROLOGICAL MANAGEMENT
  • 2002-06-01 Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2001-08-14 Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2001-04 Branched chain amino acid in adenine-induced uremic rats treated with rHuEPO in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 1999-09-24 MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas in BRITISH JOURNAL OF CANCER
  • 1999-08 Long-term prophylactic effects of intravesical instillation of thiotepa and oral administration of UFT on the recurrence of superficial bladder cancer after transurethral resection in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 1999-05 Reversibility of adenine-induced renal failure in rats in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 1999-03-12 E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion in BRITISH JOURNAL OF CANCER
  • 1998-05 Experimental and clinical study of endothelin-1 in renal failure in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 1997-09 A histopathological mapping study of the urinary bladder tumors induced byN-butyl-N-(4-hydroxybutyl)nitrosamine in dogs in UROLITHIASIS
  • 1997-07 Successful treatment of intraoperative pulmonarytumor embolism from renal cell carcinoma in HEART AND VESSELS
  • 1996-08 Urethral opening pressure in patients with myelodysplasia in SPINAL CORD
  • 1994-01 Prospective randomized study of prophylaxis of superficial bladder cancer with epirubicin: the role of a central pathology laboratory in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1992-01 A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer-intravesical thio-TEPA versus oral UFT in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1990-10 Rat urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine and N-methyl-N-nitrosourea in UROLITHIASIS
  • 1989 Neoadjuvanstherapie gegen infiltrierenden Harnblasenkrebs in 40. TAGUNG, 28. SEPTEMBER–1. OKTOBER 1988, SAARBRÜCKEN
  • 1987-11 Effects of single chemotherapeutic agents on development of urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats in UROLITHIASIS
  • 1987-08 Prophylactic treatment for superficial bladder cancer following transurethral resection in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1987-02 Scanning electron microscopy of changes in the urinary bladder in dogs treated with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in UROLITHIASIS
  • 1973-12 Effects of foreign bodies on development of urinary bladder tumors in rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine in UROLITHIASIS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.410814.8", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.26091.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.474851.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420115.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411248.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414342.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413376.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.267335.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416963.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.430387.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.258622.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.177174.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.31432.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.258799.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419953.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.261356.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.69566.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.174567.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.254229.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.20515.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.26999.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412002.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411704.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410818.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410781.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412781.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.440917.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.263171.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.505795.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.470854.a", 
            "type": "Organization"
          }
        ], 
        "familyName": "Hirao", 
        "givenName": "Yoshihiko", 
        "id": "sg:person.01005701151.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005701151.48"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-05-10T11:29", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/person/person_735.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01005701151.48'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01005701151.48'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01005701151.48'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01005701151.48'


     

    This table displays all metadata directly associated to this object as RDF triples.

    74 TRIPLES      10 PREDICATES      40 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01005701151.48 schema:affiliation Nf29e3bd23ebb4b1d8daa9a6534e1851a
    2 grid-institutes:grid.174567.6
    3 grid-institutes:grid.177174.3
    4 grid-institutes:grid.20515.33
    5 grid-institutes:grid.254229.a
    6 grid-institutes:grid.258622.9
    7 grid-institutes:grid.258799.8
    8 grid-institutes:grid.26091.3c
    9 grid-institutes:grid.261356.5
    10 grid-institutes:grid.263171.0
    11 grid-institutes:grid.267335.6
    12 grid-institutes:grid.26999.3d
    13 grid-institutes:grid.31432.37
    14 grid-institutes:grid.410781.b
    15 grid-institutes:grid.410818.4
    16 grid-institutes:grid.411248.a
    17 grid-institutes:grid.411704.7
    18 grid-institutes:grid.412002.5
    19 grid-institutes:grid.412781.9
    20 grid-institutes:grid.413376.4
    21 grid-institutes:grid.414342.4
    22 grid-institutes:grid.416963.f
    23 grid-institutes:grid.419953.3
    24 grid-institutes:grid.420115.3
    25 grid-institutes:grid.430387.b
    26 grid-institutes:grid.440917.f
    27 grid-institutes:grid.470854.a
    28 grid-institutes:grid.474851.b
    29 grid-institutes:grid.505795.b
    30 grid-institutes:grid.69566.3a
    31 schema:familyName Hirao
    32 schema:givenName Yoshihiko
    33 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005701151.48
    34 schema:sdDatePublished 2022-05-10T11:29
    35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    36 schema:sdPublisher Nc22b0937f4164da488cea9bcc25d5224
    37 sgo:license sg:explorer/license/
    38 sgo:sdDataset persons
    39 rdf:type schema:Person
    40 Nc22b0937f4164da488cea9bcc25d5224 schema:name Springer Nature - SN SciGraph project
    41 rdf:type schema:Organization
    42 Nf29e3bd23ebb4b1d8daa9a6534e1851a schema:affiliation grid-institutes:grid.410814.8
    43 sgo:isCurrent true
    44 rdf:type schema:OrganizationRole
    45 grid-institutes:grid.174567.6 schema:Organization
    46 grid-institutes:grid.177174.3 schema:Organization
    47 grid-institutes:grid.20515.33 schema:Organization
    48 grid-institutes:grid.254229.a schema:Organization
    49 grid-institutes:grid.258622.9 schema:Organization
    50 grid-institutes:grid.258799.8 schema:Organization
    51 grid-institutes:grid.26091.3c schema:Organization
    52 grid-institutes:grid.261356.5 schema:Organization
    53 grid-institutes:grid.263171.0 schema:Organization
    54 grid-institutes:grid.267335.6 schema:Organization
    55 grid-institutes:grid.26999.3d schema:Organization
    56 grid-institutes:grid.31432.37 schema:Organization
    57 grid-institutes:grid.410781.b schema:Organization
    58 grid-institutes:grid.410814.8 schema:Organization
    59 grid-institutes:grid.410818.4 schema:Organization
    60 grid-institutes:grid.411248.a schema:Organization
    61 grid-institutes:grid.411704.7 schema:Organization
    62 grid-institutes:grid.412002.5 schema:Organization
    63 grid-institutes:grid.412781.9 schema:Organization
    64 grid-institutes:grid.413376.4 schema:Organization
    65 grid-institutes:grid.414342.4 schema:Organization
    66 grid-institutes:grid.416963.f schema:Organization
    67 grid-institutes:grid.419953.3 schema:Organization
    68 grid-institutes:grid.420115.3 schema:Organization
    69 grid-institutes:grid.430387.b schema:Organization
    70 grid-institutes:grid.440917.f schema:Organization
    71 grid-institutes:grid.470854.a schema:Organization
    72 grid-institutes:grid.474851.b schema:Organization
    73 grid-institutes:grid.505795.b schema:Organization
    74 grid-institutes:grid.69566.3a schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...